Federal agencies that previously created protective backstops for health technologies have shifted their focus to supporting new risk-taking technologies, including artificial intelligence, according to the article[1]. President Donald Trump's administration has pushed policies that centralize AI regulation at the federal level and are intended to limit the ability of individual states to enact their own rules for AI[1]. As a result of the changes, agencies such as the FDA and CDC are focusing on liberalizing rules to approve technologies more quickly instead of strong preventative controls[7][10]. The article reports that the administration plans to eliminate approximately 10,000 positions in the Department of Health, affecting the capacity of regulators[4][10]. These changes include budget cuts and staff transfers that critics say reduce oversight of the safety and effectiveness of new equipment and software[5][7]. According to the article, the administration is also pushing to bring innovations to market faster and streamline regulatory procedures for health technologies[1][7]. The article does not provide new quantitative studies or empirical measurements of the effects of these policies on patient outcomes; it is primarily a description of the policy changes and their administrative implications[1][5].